April 10 (Reuters) - Silo Pharma Inc ( SILO ):
* SILO PHARMA SET TO ACQUIRE EXCLUSIVE LICENSING FOR
PROMISING
ALZHEIMER'S DISEASE THERAPEUTIC
* SILO PHARMA INC ( SILO ) - COMPANY EXPECTS TO FINALIZE AND ENTER
INTO
EXCLUSIVE LICENSE AGREEMENT IN FIRST HALF OF 2024
* SILO PHARMA INC ( SILO ) - BELIEVES THAT SPC-14 SHOULD BE ELIGIBLE
FOR
DEVELOPMENT UNDER FDA'S 505(B)(2) REGULATORY PATHWAY
* SILO PHARMA INC ( SILO ) - UNDER TERMS, SILO WILL BE GRANTED AN
EXCLUSIVE
LICENSE TO FURTHER DEVELOP, MANUFACTURE, AND COMMERCIALIZE
SPC-14 WORLDWIDE
Source text for Eikon:
Further company coverage: